Compare SY & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SY | VNDA |
|---|---|---|
| Founded | 2013 | 2002 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 276.7M | 301.1M |
| IPO Year | 2018 | 2005 |
| Metric | SY | VNDA |
|---|---|---|
| Price | $2.45 | $4.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $7.31 | ★ $11.75 |
| AVG Volume (30 Days) | 308.3K | ★ 808.4K |
| Earning Date | 11-16-2026 | 10-28-2026 |
| Dividend Yield | ★ 1.00% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $216,105,000.00 |
| Revenue This Year | $34.60 | $15.16 |
| Revenue Next Year | $36.03 | $35.50 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $1.28 | $4.27 |
| 52 Week High | $4.75 | $9.91 |
| Indicator | SY | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 41.72 | 25.65 |
| Support Level | $2.18 | N/A |
| Resistance Level | $2.89 | $5.37 |
| Average True Range (ATR) | 0.13 | 0.17 |
| MACD | -0.04 | -0.05 |
| Stochastic Oscillator | 9.61 | 3.54 |
So-Young International Inc is an aesthetic treatment platform in China connecting consumers with online services and offline treatments. Its online platform operates across multiple access points, including mobile app, Weixin mini program, and soyoung.com website, where both consumers and aesthetic practitioners can access media content, an engaging social community and a transparent reservation system. The company has four reportable segments: Aesthetic treatment services group, Platform service group, Wuhan Miracle, and Others. The majority of revenue is derived from the Platform service group, which generates revenue by providing information services and reservation services. All the company's revenues are derived from within the PRC.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.